884495-16-3

Basic information

• Product Name: 5-bromo-2-(1,3-dioxolane-2-yl)pyridine
• Synonyms: 5-bromo-2-(1,3-dioxolane-2-yl)pyridine
• CAS NO: 884495-16-3
• Molecular Weight: 230.061
• Mol File: 884495-16-3.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-(1,3-dioxolane-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(1,3-dioxolane-2-yl)pyridine(884495-16-3)
• EPA Substance Registry System: 5-bromo-2-(1,3-dioxolane-2-yl)pyridine(884495-16-3)

Safety Data

• Hazardous Substances Data: 884495-16-3(Hazardous Substances Data)

Upstream product

• 223463-13-6 2-iodo-5-bromopyridine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 107-21-1 ethylene glycol 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 897943-14-5 2-[1,3]dioxolan-2-yl-5-phenylpyridine 
• 1264748-06-2 6,6′-diformyl-3,3′-bipyridine 
• 1214336-21-6 (3,4′-bipyridine)-6-carboxaldehyde 
• 1072952-38-5 (6-(1,3-dioxolan-2-yl)pyridin-3-yl)boronic acid 

Relevant articles and documents

Simultaneous Generation of a [2 × 2] Grid-Like Complex and a Linear Double Helicate: a Three-Level Self-Sorting Process

Two constitutional dynamic libraries (CDLs) - each containing two amines, two dialdehydes, and two metal salts - have been found to self-sort, generating two pairs of imine-based metallosupramolecular architectures (sharing no component) each with a [2 ×

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS

The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.